Biotech | May 09, 2022
Roche Diabetes Care launches ACCU-FINE pen needles for virtually painless insulin delivery
Aims to increase compliance and improve outcomes for People with Diabetes (PwD)
Aims to increase compliance and improve outcomes for People with Diabetes (PwD)
The innovative Fixed-Dose Combination will help improving the glycemic control among adult patients with insulin resistance, those whose diabetes is uncontrolled by metformin; and also those who require addition of Teneliglitptin and Pioglitazone as separate drugs.
Key findings underscore the need for better control of glycemia, blood pressure and lipid parameters to prevent diabetes-related complications
The study was published recently in Genome Medicine, a leading international journal focused on translational, genomic-based medicine
In a European work-sharing procedure (WSP), Glucophage was approved as the first oral anti-diabetic medication to be used safely from conception to birth
Jardiance is the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death or hospitalization for heart failure, regardless of ejection fraction
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma
MJ will be paid a one-time lumpsum licence fee of Rs 15 crore
Jardiance is the first SGLT2-inhibitor therapy to prove reduction in risk of cardiovascular death in people with type-II diabetes and established cardiovascular disease
Subscribe To Our Newsletter & Stay Updated
